Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 3930 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

AstraZeneca reports strong Q2 growth

These results were driven by strong sales of five key growth products, namely Nexium, Seroquel, Crestor, Arimidex, and Symbicort, the combined sales of which grew by 21% in

FDA fast-tracks Pharming angioedema therapy

The fast track designation will provide an expedited review process rhC1INH. It also allows for more frequent interactions with the FDA, which could improve the efficiency of product

GSK posts Q2 profit rise

Q2 2006 profit reached GBP1.32 billion ($2.45 billion), up from GBP1.16 billion for Q2 2005. Earnings per share (EPS) hit 23.3 pence, compared to 20.2 pence for Q2

Ampakines found to help reverse memory loss

A group of scientists conducted studies on rats with a class of drugs known as ampakines. Ampakines were developed in the early 1990s by University of California researchers